Background and Purpose-Our previous study has defined a role of TP53-induced glycolysis and apoptosis regulator in neuroprotection against ischemic injury through increasing the flow of pentose phosphate pathway. We hypothesized that the pentose phosphate pathway product nicotinamide adenine dinucleotide phosphate (NADPH) could be a novel drug for treatment of ischemic stroke. Methods-The NADPH was given before, at the onset, or after stroke onset with single or repeated intravenous (mice and rats) or intraperitoneal injections (monkey). The short-and long-term therapeutic effects of NADPH were evaluated in male adult ICR mice (total=614) with transient middle cerebral artery occlusion, in male adult Sprague-Dawley rats (total=114) with permanent middle cerebral artery occlusion, and in male adult rhesus monkey (total=12) with thrombotic middle cerebral artery occlusion. Results-Administration of NADPH led to a dramatic increase in the levels of ATP and reduced form of glutathione, whereas it decreased the levels of reactive oxygen species. NADPH significantly reduced infarct volume, improved poststroke survival, and recovery of neurological functions in mouse and rat models of stroke. Robust neuroprotection of a single dose of NADPH was seen when it was administered within 5 hours after reperfusion; however, repeat administration of NADPH twice a day for 7 days starting 24 hours after the onset of stroke also offered therapeutic effects. Pretreatment with NADPH also significantly improved the outcome of stroke insult. Conclusions-Administration of exogenous NADPH significantly protected neurons against ischemia/reperfusioninduced injury in 2 rodent stroke models. Thus, NADPH might be a promising drug candidate for treatment of ischemic stroke.
I schemic stroke, the most common type of stroke, is the leading cause of death and disability in aged society, 1 and the treatment options in clinic are limited. Thrombolytic therapy with recombinant tissue-type plasminogen activator is the first line therapeutic choice in stroke management, but its clinical application is limited because of the narrow therapeutic window and side effects. 2 Less than 10% of patients with stroke will have the clinical indication for use of tissue-type plasminogen activator. Therefore, developing novel therapeutic drugs for ischemic stroke is urgently needed.
The interruption of blood flow to brain tissue during stroke attack causes a metabolic crisis, which results in reduced energy supply and a burst increase in reactive oxygen species (ROS). It is generally accepted that neurons are particularly vulnerable to ischemic injury because neurons have little activity of anaerobic glycolysis. Meanwhile, neurons consume a large amount of energy for maintaining normal neurotransmission. Many studies have indicated that oxidative stress is a key pathological player in ischemic brain injury and have proposed it as a therapeutic target. [3] [4] [5] However, previous
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studies with various antioxidants offered limited clinical efficacy in patients with stroke. 3 One possible reason is that ROS are produced inside of cells and before they are released into extracellular space, the oxidative damage of DNA, proteins and lipids have already been produced. Thus, scavenge of extracellular space ROS may have limited benefits to neurons.
TP53-induced glycolysis and apoptosis regulator was reported to inhibit glycolysis and increase the flow of pentose phosphate pathway. 6 It plays an important survival role in cancer cells. 6 Our previous studies found that TP53-induced glycolysis and apoptosis regulator was predominantly expressed in brain neurons and rapidly responded to ischemia/reperfusion insult. TP53-induced glycolysis and apoptosis regulator exerted neuroprotection against ischemic brain injury through increasing the flux of pentose phosphate pathway. 7 Nicotinamide adenine dinucleotide phosphate (NADPH), a metabolic product of pentose phosphate pathway, is a coenzyme and classic molecule involved in many anabolic reactions in cells. 8 It serves as hydrogen and electron donors in reductive biosynthesis of amino acids, lipids, and nucleotides. Another important biological function of NADPH is to provide redox power to antioxidant systems that mediate the cell response to oxidative stress. [9] [10] [11] Reduced form of glutathione is essential for the functions of key antioxidant enzyme glutathione peroxidase, 12 and NADPH is required for its regeneration. NADPH is also implicated in the production of ATP, and together with the respiratory chain-oxidized NAD, it maintains cell energy homeostasis. 9, 13 We expected that supply of exogenous of NADPH would reduce intracellular oxidative stress and improve energy supply after stroke attack. This study, thus, was sought to investigate whether supplementation of exogenous NADPH had a therapeutic effect in rodent and primate models of ischemic stroke. The results of this study strongly suggest that NADPH may be a novel therapeutic drug for stroke.
Materials and Methods
Middle Cerebral Artery Occlusion Model in Rodents
Male ICR mice (25-30 g) and male adult Sprague-Dawley rats (250-280 g) were purchased from SLACCAL Lab Animal Ltd (Shanghai, China). All animals were used in accordance with the institutional guidelines for animal use and care, and the study protocol was approved by the Ethical Committee of Soochow University. Middle cerebral artery occlusion (MCAO) surgery was performed as described previously. 14, 15 In brief, mice and rats were anesthetized with intraperitoneal injection of 1% pentobarbital sodium, the right external carotid artery was exposed, and a small incision was made. A 6-0 (for mouse) or 3-0 (for rat) monofilament nylon suture (Doccol Co, Redlands, CA) was inserted from the external carotid artery into the internal carotid artery to occlude the right MCA at its origin. Two hours after occlusion, filament was withdrawn to allow blood reperfusion. Sham-operated animals underwent identical procedures, except for the suture insertion. Cerebral blood flow was monitored (LDF, ML191 Laser Doppler Blood Flow Meter, Australia), and only those animals with 90% reduction of blood flow during MCAO and 85% to 95% recovery of blood flow during reperfusion were used ( Figure I in the online-only Data Supplement). A homoeothermic heating blanket was used to maintain the core body temperature at 37°C during ischemia/reperfusion operation. For permanent MCAO (pMCAO), the occluding filament was left in situ until the end of experiment.
Mice and rats were euthanized post ischemia/reperfusion at indicated time. Brains were harvested and stored at −80°C for further analysis.
In the experiments using rhesus monkeys (age, 6-8 years), animals were allocated to experimental groups, so that the differences in the average body weight among groups were minimized. In the experiments using mice and rats, whose body weights were relatively uniform, the animals were randomly allocated to each experimental group. The criteria for exclusion, the results of the exclusion, and mortality in each group are shown in Table I in the online-only Data Supplement. All of the evaluations and administration of drug in the experiments were performed in a masked manner.
Measurement of Infarct Volume in Rodents
The mice and rats were anesthetized with 1% pentobarbital sodium, and brains were rapidly removed 24 hours or 7 days after MCAO. Brains were sliced with plastic modules (Harvard Apparatus, MA), and sections were incubated in 1% 2,3,5-triphenyltetrazolium chloride in saline for 20 minutes at 37°C. The infarct area was measured on 5 sections (mice, 2-mm thickness; rat, 3-mm thickness) per brain using digital imaging and image analysis software (Image Pro Plus, Media Cybernetics, Silver Spring, MD) by an observer who was blinded to experimental conditions. The presence or absence of infarction was determined by examining 2,3,5-triphenyltetrazolium chloride-stained sections for the areas on the side of infarction that did not stain with 2,3,5-triphenyltetrazolium chloride. Infarct volume was expressed as a percentage of total hemisphere.
14,16
Measurement of Neurological Score and Brain Water Content After MCAO
Behavioral deficits were evaluated 24 hours after reperfusion by an observer blinded to the condition of treatments according to the method previously described. 17 The following rating scores were used: score 0, no neurological deficit; score 1, failure to extend left forepaw fully; score 2, circling to the left; score 3, falling to the left; and score 4, did not walk spontaneously and had a depressed level of consciousness. Mice and rats that did not show behavioral deficits immediately after reperfusion (neurological score, 0) were excluded from the study.
After the wet weight of the brains was quantified, the red and white parts of these brains were desiccated at 105°C for 48 hours until the weight was constant. The total weight of the dried 2,3,5-triphenyltetrazolium chloride-stained brains was obtained, and the water content of each brain was measured as follows: water content=(wet weight−dried weight)/wet weight×100%.
18
Evaluation of the Blood-Brain Barrier Integrity
The integrity of the blood-brain barrier was evaluated by using Evans blue extravasations. Evans blue (2% in saline, 4 mL/kg) was injected intravenously at 22 hours after reperfusion. The sample collection and measure protocol were followed as the previous study.
19
Thromboembolic MCAO Model in Monkeys
Twelve male adult rhesus monkeys (age, 6-8 years; weight, 6-8 kg) were purchased from Yongfu Laboratory Animal Breeding Base (Guilin, Guangxi, China). Twelve monkeys were randomly divided into 2 groups: NADPH (N7505; Sigma, Saint Louis, MO) group and saline group, 6 in each group. All animals were fasted for 24 hours with free access to water before surgery. Monkeys were intramuscularly injected with composite anesthetic (ketamine 10 mg/ kg+midazolam 1 mg/kg+scopolamine 0.02 mg/kg). Anesthetized animals were examined with magnetic resonance imaging (MRI) T2-weighted scanning before surgery to exclude intracranial lesions. After MRI scanning, all animals were sent to interventional radiological operation room with nasal oxygen, ECG, respiration, and blood pressure monitor systems. Intravenous injection of propofol was used to maintain anesthesia. Animal autologous blood (5 mL) with heparin was centrifuged for 3 minutes, and the upper by guest on November 18, 2017 http://stroke.ahajournals.org/ Downloaded from layer serum was collected. Serum was added with coagulase and injected into an epidural anesthesia tube (1 mm diameter; Henan Camel Medical Device Company, Xinxiang City, China) to make blood clots. The femoral artery was punctured using the Seldinger technique, and the microcatheter was introduced to the compartment M2 segment of MCA through a 4F guiding catheter (all catheter and guidewire were from Cordis corporation production [New York]). The blood flow was monitored with MCA angiography. The 3-cm length of blood clot was injected into MCA through the microcatheter. The occlusion of blood flow was confirmed with angiography. After 30 minutes of MCAO, the NADPH group was administered 1 mg/kg of NADPH by intraperitoneal injection. All monkey procedures were approved by the Ethical Committee of Guilin Medical College Affiliated Hospital.
Measurement of Infarct in Monkeys With MRI
MRI was performed in all animals with 3T (Magnetom Verio; Siemens Medical Systems) equipped with a 32-channel system, axial slice scanning. MRI sequences and parameters are detailed in Table  I in the online-only Data Supplement. Both T2WI and diffusionweighted imaging were taken 2 hours after MCAO. Animals were then awakened and allowed to recover. All animals were reanesthetized and scanned 24 hours and 10 days after MCAO. The ischemic brain tissue also showed a high signal in diffusion-weighted imaging, but the infarct area in T2WI was seen clearer than that in diffusionweighted imaging because of the brighter pixels; so we defined the infarct area using T2WI images. All images were amplified to outline the boundary of infarction and the infarct area then be measured using a MRI workstation.
Measurement of NADPH Levels
Mice were intravenously administered with NADPH (2.5 mg/kg). Mice (6 per group) were anesthetized with 1% pentobarbital sodium and decapitated. Brains were removed and immediately dissected on a cooled ice pack (−20°C) at the indicated time. Brain and blood NADPH concentrations were measured at the indicated time with the enzychrom NADPH/NADP assay kit (BioAssay Systems, Hayward, CA) following manufacturer's instructions.
Measurement of ATP Levels
Mice were intravenously administered with NADPH (7.5 mg/kg) at the onset of reperfusion. Mice (6 per group) were anesthetized with 1% pentobarbital sodium and decapitated 3 hours after MCAO/reperfusion. Brains were removed and immediately dissected on a cooled ice pack (−20°C). In each hemisphere, the whole-ischemic cortex (infarct tissue and penumbra tissue) was collected and quick frozen in liquid nitrogen. The ATP content in cortex was measured at 3 hours after reperfusion with the ATP assay kit (Beyotime, Nantong, China) following manufacturer's instructions.
Measurement of ROS
For assessing ROS in vivo, dihydroethidium (2 mg/kg, Sigma) was injected intraperitoneally 1 hour before the end of experiment. Mice were anesthetized and decapitated, and brain sections (10 μm) were cut with a cryostat (Leica). The dihydroethidium fluorescence in brain sections was observed with a fluorescence microscope (Olympus, Tokyo, Japan).
Statistical Analysis
Data were presented as mean±SEM and were evaluated with 1-way ANOVA with Bonferroni multiple comparisons post hoc test for comparisons of >2 means and unpaired Student t test if the statistical differences between 2 groups were compared. Differences in survival rates were assessed using the Log-rank test followed by Holm-Sidak method for all pair-wise multiple comparisons. The multiple comparison methods are described in the figure legends. A difference was considered statistically significant when P<0.05.
Results
Exogenous NADPH Performs Biological Functions
To test whether exogenous NADPH can get into mouse brain tissues and neurons, normal mice were given intravenous injection of NADPH of 2.5 mg/kg and the concentrations of NADPH in plasma and brain were determined. The results showed that the injection of NADPH significantly increased NADPH levels in mouse blood and brain tissues. The half-life of NADPH was ≈6 hours in mouse blood ( Figure 1A ) and 7 hours in brain tissues ( Figure 1B) . Next, we determined whether exogenous NADPH produced biological functions under ischemia and reperfusion conditions. The supply of NADPH did not elevate ATP levels under normal conditions. However, ATP levels in mouse brain were markedly decreased after ischemic attack. Intravenous administration of NADPH significantly increased brain ATP levels during reperfusion period ( Figure 1C ). Dihydroethidium staining is a reliable method for detecting ROS production. 20 NADPH administration significantly reduced the number of dihydroethidiumpositive cells and intensity of dihydroethidium staining in the ischemic brain sections ( Figure 1D ). Moreover, the levels of NADPH and reduced form of glutathione in brains of control mice were significantly decreased during reperfusion but were Normal mice were intravenously injected with NADPH (2.5 mg/ kg), and the half-life of NADPH in the plasma and brain was ≈6 and 7 hours, respectively. *P<0.05, **P<0.01, and ***P<0.001 vs vehicle (saline) by 1-way ANOVA with Bonferonni post hoc test. C, The effects of NADPH on ATP levels in mouse ischemic cortex 3 hours after reperfusion. NADPH (7.5 Figure IIC in the online-only Data Supplement).
To determine whether NADPH penetrates into the plasma membrane of neurons, NADPH was added to cultured mouse cortical neurons and intracellular NADPH was measured. The results showed that intracellular NADPH concentration in cultured mouse cortical neurons was significantly increased 2 hours after the addition of exogenous NADPH ( Figure IID in the online-only Data Supplement). To further demonstrate whether the biological actions of exogenous NADPH were produced in the neurons, cortical primary neurons were exposed to oxygen-glucose deprivation/reoxygenation and the effects of NADPH on neuronal bioenergy homeostasis were determined. The results showed that NADPH did not change the ATP level in neurons under normal conditions. However, NADPH induced a drastic increase in the ATP level in the neurons 3 hours after oxygen-glucose deprivation/reoxygenation ( Figure IIE in the online-only Data Supplement). The results also indicated that NADPH had no effect on neuronal survival as measured 3 hours after reoxygenation and dead cells did not produce ATP ( Figure  IIE and IIF in the online-only Data Supplement). These data suggest that NADPH can increase the production of ATP in survival neurons when oxygen becomes available again. There was a significant decrease in reduced form of glutathione levels in the cortical neurons after oxygen-glucose deprivation/reoxygenation when compared with control, whereas higher levels of reduced form of glutathione were observed in the neurons that were treated with NADPH ( Figure IIG in the online-only Data Supplement). Moreover, the ROS levels in primary neurons (dihydroethidium-positive cells) were significantly increased to ≈6-folds when compared with their control group. The treatment of neurons with NADPH reduced ROS levels ( Figure IIH and III in the online-only Data Supplement). These studies confirmed that exogenous NADPH could get into neurons to perform its biological functions.
To test whether NADPH has other novel biological actions, we determined the in vivo and in vitro effects of NADPH on platelet aggregation. We found that pretreatment with NADPH for 30 minutes in rats dramatically suppressed the ADP-induced platelet aggregation ( Figure IIIA and IIIB in the online-only Data Supplement). Meanwhile, we demonstrated that in vitro administration of NADPH (30-90 μmol/L) also inhibited ADP-induced platelet aggregation in a dose-dependent manner ( Figure IIIC and IIID in the online-only Data Supplement). In addition, we also found that treatment with NADPH 30 minutes after pMCAO mildly increased cerebral blood flow in ischemic hemisphere ( Figure IIIE and IIIF in the online-only Data Supplement).
Exogenous NADPH Reduces Ischemic Injury in 2 Rodent Stroke Models
We then asked whether exogenous NADPH could be a therapeutic agent for stroke treatment. We used a mouse brain ischemia/reperfusion model to determine the dose-response of the exogenous NADPH on brain ischemic injury. Mice were intravenously administered with NADPH 2.5, 5, and 7.5, mg/kg (immediately at reperfusion), and infarct volume and neurological deficits were assessed 24 hours after ischemic insult. The data showed that NADPH reduced infarct volume from 59.99±2.77% to 39.61±4.03%, 38.36±3.69%, and 30.41±4.10%, respectively (P<0.05 and P<0.01 compared with vehicle [model] mice; Figure 2A and 2B). The administration of NADPH also markedly attenuated ischemia/ reperfusion-induced behavioral deficits and increases in water content (P<0.05 and P<0.01 compared with vehicle mice; Figure IVA and IVB in the online-only Data Supplement). To further confirm the protective effect, we evaluated the efficacy of NADPH in mice and rats using filament-induced pMCAO, a procedure in which no complete blood reperfusion occurs. 21 Administration of NADPH 1 hour after pMCAO also decreased infarct volume to 34.81±4.83% from 59.08±2.11% (P<0.01; Figure 4A ), behavioral score to 1.93±0.15 from 2.87±0.24 (P<0.01; Figure , and water content (C) 24 hours after reperfusion. A single dose of NADPH (7.5 mg/kg) was intravenously administered at the onset of reperfusion. Multiple doses of NADPH (7.5 mg/kg) were intravenously administered at the onset, 4, and 8 hours after reperfusion, respectively. **P<0.01 and ***P<0.001 vs vehicle by 1-way ANOVA with Bonferonni post hoc test. There were 12 animals in each group. D, The effects of the single dose and multiple doses of NADPH on poststroke survival rate 28 days after stroke. *P<0.05 vs vehicle by using Log-rank test. There were 11 animals in each group. Single dose of NADPH (7.5 mg/kg) was intravenously administered at the onset of reperfusion. Multiple doses of NADPH (7.5 mg/kg) were intravenously administered at the onset, 8 hours after reperfusion, and then twice a day for 3 weeks. Data are expressed as mean±SEM. Nicotinamide adenine dinucleotide phosphate (NADPH) reduced ischemic injury in mouse and rat models of permanent focal cerebral ischemia. A, NADPH reduced infarct volume and neurological deficits (B) in mice 24 hours after permanent middle cerebral artery occlusion (pMCAO). Mice were intravenously administered with NADPH (7.5 mg/kg) 1 hour after pMCAO. C, NADPH reduced infarct volume and neurological deficits (D) in rats 24 hours after pMCAO. Rats were intravenously administered with NADPH (7.5 mg/kg) 1 hour after pMCAO. Data were expressed as mean±SEM. P values by unpaired Student t test are shown. There were 15 mice or 12 rats animals in each group. 
Preliminary Observations of the Effects of Exogenous NADPH in a Primate Stroke Model
To test the therapeutic potential of NADPH in primates, we evaluated the neuroprotective effects of NADPH in rhesus monkeys with thrombotic occlusion of M3 segment of brain MCA. 22 Representative MRI scanning images showed that NADPH administration (1 mg/kg) reduced ischemia-induced infarct areas ( Figure 5A ). Quantification of serial brain images revealed that NADPH significantly reduced the infarct volume from 5.53±0.94 mm 3 to 2.69±0.84 mm 3 24 hours after ischemic onset (P<0.05; Figure 5B ). To examine the long-term benefit, we quantified infarction areas and found that NADPH administration significantly reduced infarction areas in the cortex 10 days post ischemia ( Figure 5C ). Higher clinical examination rating scores were observed in saline-treated monkeys at 24 hours after ischemia, which was ameliorated in NADPH-treated monkeys (P<0.01; Figure 5D ). The amelioration of rating scores by single dose of NADPH persisted for 29 days after ischemic attack (Figure VIII in the online-only Data Supplement).
Prestroke or Poststroke Treatment With Exogenous NADPH Produces Robust Beneficial Effects
To determine whether preventive treatment with exogenous NADPH had a beneficial effect on the outcome of ischemic stroke, mice were intravenously administered with 7.5 mg/ kg of NADPH twice a day for 7 days. Mice were subjected to ischemia/reperfusion insult and infarct volume, and neurological deficits were assessed 24 hours after ischemic insult. No NADPH was given during and post stroke. The result showed that ischemia/reperfusion-induced infarct volume and neurological deficits were markedly reduced by pretreatment with NADPH ( Figure 6A and 6B) . The Evans blue extravasation and brain water content were significantly induced 24 hours post ischemia/reperfusion by pretreatment with NADPH ( Figure 6C ; Figure IXA in the online-only Data Supplement). Furthermore, we examined whether continuous administration of NADPH after stroke offers beneficial effects on recovery of neurological functions. The NADPH (7.5 mg/kg) was given twice daily for 14 days starting 24 hours after stroke insult. The results showed that NADPH significantly increased the long-term survival rate and the recovery of motor and cognitive functions and 28 days post ischemia/reperfusion (Figure IXB-IXE in the online-only Data Supplement). The morphological examination demonstrated that exogenous NADPH notably decreased the shrinkage of the ischemic hemisphere ( Figure 6D ).
Discussion
This study demonstrated, for the first time, that systemic administration of exogenous NADPH significantly protected neurons against ischemia/reperfusion-induced injury in 2 rodent stroke models. It not only substantially reduced infarct volume after stroke insult but also significantly reduced long-term mortality and improved recovery of neurological functions. The extent of neuroprotection offered by NADPH is exceptional, and the therapeutic window of NADPH efficacy is much larger than that of tissue-type plasminogen activator 23 in rodent models. NADPH could also be used for preventive treatment to reduce ischemic injury and poststroke treatment to improve survival of animals and recovery of neurological functions in rodent models. The acute toxicity of NADPH seemed to be low as mice could tolerate approximately a 400-fold increase of its therapeutic dose (Mice were slowly injected with NADPH [1, 2 or 3 g/kg] via tail vein. No animal died after the drug administration. Twenty mice were used in this preliminary experiment). Therefore, we propose that NADPH may be a novel drug candidate for stroke therapy. This notion is strongly supported by several unique features of NADPH and its biological functions.
Effective therapeutic agents for the treatment of stroke must enter into the brain parenchyma through the blood-brain barrier, which is one of the major obstacles for treating central nervous system diseases. 24 This study demonstrated that NADPH levels in brains were increased after intravenous injection of NADPH. This study further demonstrated that addition of NADPH in culture medium significantly increased intracellular NADPH. Furthermore, administration of exogenous NADPH increased the levels of reduced form glutathione and ATP, suggesting that NADPH can effectively penetrate the blood-brain barrier and cell membranes to produce biological functions. It should be pointed out that the brain NADPH we measured in this study might only reflect NADPH accumulation in the vasculature but not in the brain cells.
One of the functions of NADPH is to produce reduced form of glutathione. This property enables exogenous NADPH to block the elevation of intracellular ROS levels during ischemia/reperfusion. In addition, when oxygen is available, excess NADPH can be used by mitochondria for production of ATP. 9 A rapid recovery of ATP levels after ischemic insult certainly favors rescue of neurons to avoid irreversible injury. In an attempt to find novel biological actions of NADPH, we evaluated whether NADPH inhibits platelet aggregation. A complete blockade of cerebral blood flow in our MCAO and pMCAO models was reached because of the formation of blood clot around the head of inserted nylon suture. Thus, inhibition of platelet aggregation may suggest that NADPH could improve blood supply to ischemic hemisphere. In fact, a slight increase in blood flow to ischemic cortex was observed 
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One of the big challenges in stroke management is missing the optimal therapeutic window when patients administered into hospital. This study demonstrated that a single dose of NADPH remained effective if administered within 5 hours after onset of reperfusion. However, NADPH still produced therapeutic benefits when administered 24 hours after onset of stroke if multiple dosages were used for prolonged time period. To test the rationale for preventive use of NADPH, we administered NADPH twice a day for 1 week and stopped the treatment on the day of onset of stroke and thereafter. The results demonstrated that preventive treatment with NADPH robustly reduced ischemic injury and improved long-term survival and recovery of neurological functions. Thus, NADPH could be a drug for acute treatment, preventive treatment, and poststroke treatment.
As no single animal model can completely mimic the pathology of human ischemic stroke, multiple animal models were used for evaluation of short-and long-term therapeutic effects of NADPH in the present study. The short-and longterm therapeutic effects of NADPH were verified in multiple animal stroke models. As people may argue that in human patients with stroke, complete reperfusion of blood may not occur; thus, this study tested the protective effects of NADPH in mouse and rat models of pMCAO, in which blood flow was permanently interrupted. The results demonstrated that NADPH reduced infarct volume, increased long-term survival, and recovery of neurological functions. Considering the fundamental differences between rodent brains and human brains, we also evaluated the therapeutic effects of NADPH in a primate stroke model, which represents the best model for human ischemic stroke. 22 In this model, focal blood flow was blocked by direct injection of a thrombus into the midbrain artery. This procedure produced brain infarct in the territory supplied by M3 segment of middle brain cerebral artery. The initial studies showed that NADPH was effective as evidenced by reductions in infarct volume and neurological deficits. However, only limited number of monkeys was used in this study, and the infarct area was small with current protocol. The efficacy of NADPH in primates remains to be further confirmed.
It should also be pointed out that there are additional flaws in this study. The selection of dosage of NADPH in mice, rats, and monkeys was not carefully converted according to pharmacokinetics in different species in this study. The routes of NADPH administration in rodents and monkeys were also different. These pitfalls might affect the reliability of the study. Furthermore, except for antioxidative stress offered by NADPH, the other mechanisms that may also be responsible for NADPH's robust neuroprotective effects remain to be further determined.
Conclusions
This study showed that NADPH offered robust short-and long-term therapeutic effects in 2 rodent stroke models.
NADPH may have clinical advantages as it has a relatively big therapeutic window, low acute toxicity, and no risk of cerebral breeding. NADPH had neither beneficial nor harmful effect on a hemorrhage stroke model (our unpublished observations). The biological actions of NADPH also strongly suggest that NADPH may prolong tissue-type plasminogen activator's therapeutic window and prevent secondary injury associated with reperfusion after thrombolysis. Thus, NADPH might be a promising drug candidate for therapeutic intervention of cerebral ischemia.
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SUPPLEMENTAL MATERIAL
Oxygen-glucose deprivation/reoxygenation (OGD/R)
The cultured primary neurons (8 days) were rinsed 3 times with phosphate-buffered saline (PBS) and incubated with glucose-free Hank's balanced salt solution (HBSS) (in mM) 116 NaCl, 5.4 KCl, 0.8 MgSO 4 , 1.0 NaH 2 PO 4 , 1.8 CaCl 2 , and 26 NaHCO 3 (pH 7.3) and placed in an ischemic chamber (Billups-Rothenberg, MC-101, San Diego, CA, USA) that was filled with 95% N 2 and 5% CO 2 at 37°C. Control cells were placed in HBSS containing 3 mM D-glucose and incubated under normal culture conditions for the same time period. After OGD 4 h, cultures were replaced with the normal culture medium and cultured under normal conditions (reoxygenation) for 24 h. NADPH (10 M) was added immediately at reoxygenation to study its biological effects in neurons.
Measurement of ATP levels
Primary neurons were cultured in 6-well plates for 8 days and subjected to OGD/R as described above. NADPH (10 M) was added to cultured primary neurons at the onset of OGD/R. ATP contents in the cell lysates of cultured primary neurons and extracellular medium were measured at 3 h after reoxygenation with the ATP assay kit (Beyotime, Nantong, China) following manufacturer's instructions.
Measurement of ROS
Primary neurons were cultured and subjected OGD/R as described above, intracellular ROS was measured 3 h after reoxygenation by incubation with 1 μM DHE (Sigma) for 30 min at 37°C. Fluorescence intensity was measured with a laser confocal microscope (Olympus, Tokyo, Japan).
Measurement of NADPH and rGSH levels
Mice were intravenously administered with NADPH (7.5 mg/kg) at the onset of reperfusion. Mice (six per group) were anesthetized with 1% pentobarbital sodium and decapitated. Brains were removed and immediately dissected on a cooled ice pack (−20°C) at the indicated time after reperfusion. Brain NADPH and rGSH concentrations were measured at the indicated time after reperfusion with the enzychrom NADPH/NADP assay kit (BioAssay Systems, Hayward, CA, USA) and the GSH kit (Beyotime) following manufacturer's instructions. To investigate if the exogenous NADPH penetrates into brain tissue through the blood-brain-barrier, mice were intravenously administered with NADPH (7.5 mg/kg) at the onset of reperfusion. Mice (six per group) were anesthetized with 1% pentobarbital sodium and perfused with pre-cooled phosphate-buffered saline (PBS, pH 7.4) to remove blood. The levels of NADPH in mice brains with or without perfusion were measured at the indicated time after reperfusion with the enzychrom NADPH/NADP assay kit.
Cultured primary neurons (8 th day) were treated with NADPH (10 M) at the onset of OGD/R. Intracellular NADPH and GSH concentrations were measured 3 h after reoxygenation using the enzychrom NADPH/NADP assay kit and the GSH kit (Beyotime). To determine penetration of NADPH into neurons, primary neurons were plated in 6-well plates, cultured primary neurons (8 th day) were treated with NADPH (10 M) at the onset of OGD/R. Cells were washed three times with ice-cold phosphate-buffered saline 3 h after reoxygenation, then neurons were lyzed and NADPH was measured with the NADPH/NADP assay kit. The NADPH in 3 supernatant after the third wash was also determined and fund that supernatant had no NADPH, indicating that all extracellular NADPH was removed.
Cell viability assay
Primary neurons were plated in 96-well plates, cultured primary neurons (8 th day)
were treated with NADPH (10 M) at the onset of OGD/R. Cell viability of cultured primary neurons was evaluated 3 h after reoxygenation with a nonradioactive cell counting kit (CCK-8; Do-Jindo) according to manufacturer's protocols.
Platelet aggregation test
In vitro or in vivo whole blood was collected from the vena cava of the normal rats and rat injected intravenously with NADPH (7.5mg/kg) or saline for 30 min and anti-coagulated with acid-citrate-dextrose buffer (9:1, v/v). Platelet-rich plasma (PRP) was obtained by centrifugation of the blood at 250 g for 15 min. To obtain platelet-poor plasma (PPP), the remaining blood sample was further centrifuged at 2000 g for 15 minutes. The pallets were washed 3 times with a modified Tyrode's buffer without Ca 2+ (134 mM NaCl, 3 mM KCl, 0.3 mM NaH 2 PO4, 2 mM MgCl 2 , 5 mM HEPES, 5 mM glucose, 12 mM NaHCO 3 , 1 mM EGTA, and 3.5 mg/mL BSA). Platelet number was adjusted to a final concentration at 2 x 10 8 cells/ml. Platelet aggregation was measured using a Chrono-Log 590 Aggregation System (Chrono-Log, Havertown, PA, USA) with stirring at 37 °C. Platelet aggregation was induced with adenosine diphosphate (ADP, 20 µM, Sigma), and recorded the change of transmission. Platelet aggregability was evaluated by the maximal percent of platelet aggregation.
Behavioral tests
In all animals, a battery of behavioral tests (Beam walk test, Rotor-rod test and The Y-maze task) was performed 7 or 28 days after pMCAO or MCAO as described previously [2] [3] [4] by two investigators who were blinded to the experimental conditions.
Histopathological evaluation
Histopathological examination was performed on the brain tissues of all groups as previously described 5 . At 4 weeks after ischemia, the mice were anesthetized using sodium pentobarbital and sacrificed. The brains were then dissected. Frozen brain sections (10 m) were cut with a cryostat (Leica, NuBloch, Germany) and fixed in 4% paraformaldehyde, then stained with hematoxylin-eosin (H&E) for histological examination. Rats subjected to post-ischemia for 1 week were perfusion-fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) under anesthesia. Brains were removed quickly and further fixed with the same fixation solution overnight at 4 °C. Brain sections (20 μm thick) were cut with a cryostat (Leica) and stained with 0.1% (w/v) cresyl violet and examined with a light microscopy to assess neuronal damage. The number of surviving cortical neuronal cell per mm was counted as the neuronal density. Histological examinations were performed with light microscopy by two investigators who were blinded to the experimental conditions. NHPSS scores NHPSS scores in monkeys that subjected to stroke were evaluated by an observer with experience in evaluating neurologic deficit who was blinded to the treatment conditions 24 h after MCAO and up to 29 days of post-survival time with the 4 following subcategorized parameters: consciousness, defense reaction, grasp reflex, and extremity movement, gait, circling, bradykinesia, balance, neglect, visual field cut/hemianopia, facial weakness 6 . Defense reaction is a complex response which included sharp movement away from a threat, lifting the head and opening of the mouth enough to show the canines. The stimulus for the visual field evaluation was a piece of fruit presented from each side, with the examiner directly facing the animal in its home cage. Normal response to this stimulus is turning the gaze and the head toward it and usually reaching for the food. Blinking reflex is elicited by rapid approach of a stimulus from the periphery toward the eye. Bradykinesia and circling was self-explanatory. All the assessments were done in the home cage. From a total of 41 points, 0 corresponded to normal behavior and 41 to severe bilateral neurological impairment 6 .
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Supplemental Figure Ⅰ.
Representative of cerebral blood flow of mice exposed to MCAO for 120 min and reperfusion.
7 Supplemental Figure Ⅱ . Exogenous NADPH entered into neuronal cells and reduced oxidative stress. A, B, The changes in NADPH (A) and rGSH (B) levels in mouse ischemic mouse cortex. Mice were injected with NADPH (i.v., 7.5 mg/kg) at the onset of reperfusion. *P < 0.05, **P < 0.01, ***P < 0.001 vs vehicle by one-way ANOVA with Bonferonni's post hoc test. There were six animals in each group. C, The changes in NADPH levels in mouse ischemic mouse cortex 3 h after reperfusion. Mice were injected with NADPH (i.v., 7.5 mg/kg) at the onset of reperfusion. Mice were perfused with PBS to remove blood in brains. ***P < 0.001 vs sham, ## P < 0.01 vs vehicle by one-way ANOVA with Bonferonni's post hoc test. There were six animals in each group. D, Increase in NADPH content in cultured primary neurons. The neurons were cultured for 8 days, then NADPH (10 M) were added to culture medium for 2 h, and they were rinsed with PBS and lyzed for determination of NADPH content. ***P < 0.001 vs control by one-way ANOVA with Bonferonni's post hoc test. E, F, The effects of NADPH on ATP content (E) and neuronal survival (F) of neurons 3 h after reoxygenation. NADPH (10 M) was added to cell culture medium at the onset of reoxygenation. ***P < 0.001 vs cont, # P < 0. and water content (B) 24 h after reperfusion. Mice were subjected to tMCAO for 2 h, and NADPH (2.5, 5 and 7.5 mg/kg) was administered by tail vein injection immediately after reperfusion. *P < 0.05, **P < 0.01, ***P < 0.001 vs vehicle by one-way ANOVA with Bonferonni's post hoc test. Neurological deficits (C) and water content (D) 24 h after reperfusion. Mice were intravenously administered with NADPH (7.5 mg/kg) at 0, 2, 4, 5, 6, and 7 h after reperfusion, respectively. *P < 0.05, **P < 0.01, ***P < 0.001 vs vehicle by one-way ANOVA with Bonferonni's post hoc test. Data were expressed as mean ± s.e.m. There were fifteen animals in each group. Supplemental Figure Ⅶ . NADPH administration reduced ischemia-induced neurological deficits and increases in brain water content in mouse and rat models of permanent focal cerebral ischemia. Water contents (A) in mice 24 h after pMCAO. Mice were intravenously administered with NADPH (7.5 mg/kg) 1 h after pMCAO. Water content (B) in rats 24 h after pMCAO. Rats were intravenously administered with NADPH (7.5 mg/kg) 1 h after pMCAO. P-values by unpaired Student's-test were shown. There were fifteen animals in each group. C, NADPH reduced infarct volume as measured on cresyl violet-stained brain sections in rats 7 days after pMCAO. D, cell density was expressed as the number of cells per 1-mm length of the brain sections counted with a light microscopy. ***P < 0.001 vs sham, ### P < 0.001 vs vehicle by one-way ANOVA with Bonferonni's post hoc test. Scale bar = 100 m. There were six rats animals in each group. The effects of post-stroke treatment with NADPH on neurological deficits (E) in rats 7 days after pMCAO. *P <0.05, **P <0.01 vs vehicle by two-way ANOVA with Bonferonni's post hoc test. F, Post-stroke survival rate 7 days after stroke of rats that subjected to pMCAO. The difference was significant (P=0.034 by using log-rank test). There were twelve (E, F) rats animals in each group. Multiple doses of NADPH (7.5 mg/kg) were intravenously administered at the onset, 8 h after reperfusion and then twice a day for 3 weeks. P-values by unpaired Student's t-test were shown. Data were expressed as mean ± s.e.m. В ранее проведенных исследованиях мы доказали, что регулятор TP53-индуцированного гликолиза и апоптоза преимущественно экспрессируется в нейронах голов-ного мозга и быстро реагирует на развитие ишеми-ческого и реперфузионного повреждений. Регулятор TP53-индуцированного гликолиза и апоптоза оказыва-ет нейропротекторное действие при ишемическом по-вреждении головного мозга за счет увеличения числа мета-болитов пентозофосфатного пути [7] . Никотинамид -адениндинуклеотидфосфат (НАДФ), мета болический продукт пентозофосфатного пути, является кофермен-том и классической молекулой, участвующей во многих анаболических реакциях в клетках [8] . Он служит доно-ром водорода и электронов при восстановительном био-синтезе аминокислот, липидов и нуклеотидов. Другой важной биологической функцией НАДФ является обес-печение работы окислительных и восстановительных антиоксидантных систем, опосредующих реакцию кле-ток на оксидантный стресс [9] [10] [11] . Восстановленная форма глутатиона имеет большое значение для функ-ционирования ключевого антиоксидантного фермента глутатион-пероксидазы [12] , и НАДФ необходим для его регенерации. НАДФ также участвует в образова-нии АТФ и вместе с окисленным в дыхательной цепи НАД сохраняет гомеостаз энергии в клетках [9, 13] . _ Мы предположили, что введение экзогенного НАДФ приведет к уменьшению выраженности внутриклеточно-го оксидантного стресса и улучшению энергетического обмена после инсульта. Таким образом, цель настоящего исследования заключалась в изучении терапевтического эффекта введения экзогенного НАДФ в моделях ИИ у грызунов и приматов. Результаты проведенного иссле-дования убедительно свидетельствуют о том, что НАДФ может быть новым терапевтическим препаратом для лечения инсульта.
Supplemental
■ МАТЕРИАЛЫ И МЕТОДЫ Модель окклюзии средней мозговой артерии у грызунов Самцов мышей линии ICR (25-30 г) и взрослых сам-цов крыс линии Sprague-Dawley (250-280 г) приобрели в лаборатории SLACCAL Lab Animal Ltd (Шанхай, Китай). Всех животных использовали в соответствии с Руководством по использованию и уходу за лабора-торными животными нашего учреждения, и прото-кол исследования был одобрен Комитетом по этике Университета Сучжоу. Операция по выполнению окклюзии средней мозговой артерии (ОСМА) была описана ранее [14, 15] . Мышам и крысам выполняли анестезию посредством интраперитонеальной инъек-ции 1% пентобарбитала натрия, посредством неболь-шого разреза обеспечивали доступ в правую наружную сонную артерию. В наружную сонную артерию вводи-ли нейлоновую монофиламентную нить (Doccol Co, Redlands, Калифорния) размером 6-0 (для мышей) или 3-0 (для крыс) для окклюзии правой СМА в ее устье. Через 2 часа после окклюзии нить удаляли для обеспечения реперфузии. Животным в группе ложного вмешательства проводили аналогичные про-цедуры за исключением введения монофиламентной нити. Осуществляли мониторинг церебрального кро-вотока (LDF, ML191 Laser Doppler Blood Flow Meter, Австралия), и для эксперимента использовали только тех животных, у которых произошло снижение крово-тока при ОСМА на 90% и восстановление кровотока при реперфузии на 85-95% (рис. I в дополнительных данных on-line). Для поддержания температуры тела на уровне 37 °С во время операции по индукции ишемии/реперфузии использовали гомеотермичес-кое подогреваемое одеяло. В модели стойкой ОСМА (сОСМА), монофиламентную нить не удаляли до окон-чания эксперимента. Мышей и крыс забивали после индукции ишемии/реперфузии в определенные сроки. Извлекали головной мозг и хранили его при темпера-туре -80 °С для проведения дальнейших анализов.
В экспериментах с использованием макак-резусов (возраст 6-8 лет) животных разделили на эксперимен-тальные группы таким образом, что различия в средней массе тела между группами были сведены к минимуму. В экспериментах с использованием мышей и крыс, масса тела которых была приблизительно одинакова, животных распределяли в каждую эксперименталь-ную группу случайным образом. Критерии исключе-ния, результаты исключения и показатели летальности в каждой группе приведены в таблице I в дополнитель-ных данных on-line. Все анализы и введение препарата осуществлялось при ослеплении относительно условий эксперимента.
Измерение объема очага ишемии у грызунов
Мышам и крысам проводили анестезию с введением 1% пентобарбитала натрия, и головной мозг быстро извлекали через 24 часа или 7 дней после ОСМА. Мозг разрезали с помощью пластиковых модулей (Harvard Apparatus, Массачусетс), срезы инкубировали в 1% раст-воре 2,3,5-трифенилтетразолинхлорида в физиологичес-ком растворе в течение 20 минут при температуре 37 °С. Зону инфаркта по 5 срезам (мыши, толщина 2 мм; крысы, толщина 3 мм) головного мозга с использова-нием программного обеспечения для цифровой визуа-лизации и анализа изображений (Image Pro Plus, Media Cybernetics, Silver Spring, Мериленд) измерял эксперт, ослепленный относительно условий эксперимента. Наличие или отсутствие очага инфаркта определяли путем анализа окрашенных 2,3,5-трифенилтетразолин-хлоридом участков головного мозга на стороне зоны ишемии и их сравнивания с неокрашенными участками. Объем очага инфаркта выражали в процентах от общего объема полушария [14, 16] .
Оценка по неврологической шкале и определение содержания воды в головном мозге после ОСМА Через 24 часа после реперфузии поведенческий дефицит оценивал эксперт, ослепленный относитель-но условий проведения эксперимента, с помощью описанных ранее методов [17] . Использовали следую-щую систему оценок: 0 баллов -отсутствие неврологи-ческого дефицита; 1 балл -невозможность полностью опираться на левую лапку; 2 балла -западание влево ЭКСПЕРИМЕНТАЛЬНО-ТЕОРЕТИЧЕСКИЕ ВОПРОСЫ при ходьбе; 3 балла -падение на левую сторону при ходьбе; 4 балла -отсутствие возможности спонтан-ного передвижения и нарушение уровня сознания. Мышей и крыс без поведенческого дефицита сразу после реперфузии (оценка по неврологической шкале 0 баллов) исключили из исследования.
После количественной оценки веса головного мозга во влажном состоянии красную и белую части мозга высу-шивали при температуре 105 °С в течение 48 часов до тех пор, пока вес не становился постоянным. Рассчитывали общий вес высушенного головного мозга, окрашен-ного 2,3,5-трифенилтетразолинхлоридом, содержание воды в головном мозге каждого животного определяли по следующей формуле: содержание воды=(вес во влажном состоянии-вес в высушенном состоянии)/вес во влажном состоянии ×100% [18] .
Оценка целостности гематоэнцефалического барьера
Целостность гематоэнцефалического барьера оцени-вали с помощью изучения экстравазации синего кра-сителя Эванса. Синий краситель Эванса (2% в физио-логическом растворе, 4 мл/кг) вводили внутривенно через 22 ч после реперфузии. Процедура отбора проб и протокол измерений описаны в ранее проведенном исследовании [19] .
Модель тромбоэмболической ОСМА у обезьян
Двенадцать взрослых самцов макак-резус (воз-раст 6-8 лет; вес 6-8 кг) приобрели в питомнике Yongfu Laboratory Animal Breeding Base (Гуйлинь, Гуанси, Китай). Двенадцать обезьян рандомизирова-ли в 2 группы: группу НАДФ (N7505; Sigma, Сент-Луис, Миссури) и группу физиологического раствора, по 6 животных в каждой группе. Перед операцией все животные голодали в течение 24 ч при свободном доступе к воде. Обезьянам внутримышечно вводили композит-ный анестетик (кетамин 10 мг/кг+мидазолам 1 мг/кг+ скополамин 0,02 мг/кг). В состоянии наркоза перед операцией животным проводили магнитно-резонанс-ную томографию (МРТ) с получением Т2-взвешенных изображений. После МР-сканирования всех животных отправляли в палату интервенционной радиологии, оснащенную аппаратом для интраназального поступ-ления кислорода и системой для мониторинга ЭКГ, дыхания и уровня артериального давления. Для про-дления анестезии использовали внутривенную инъек-цию пропофола. Аутологичную кровь животных (5 мл) с гепарином центрифугировали в течение 3 минут, и собирали верхний слой сыворотки. В сыворотку добавляли коагулазу и вводили через трубку для эпи-дуральной анестезии (диаметром 1 мм; Henan Camel Medical Device Company, Синьсян, Китай) для индук-ции тромбообразования. Пункцию бедренной артерии проводили по методу Сельдингера и проводили мик-рокатетер к М2 сегменту СМА через направляющий катетер (все катетеры и проводники были произведены корпорацией Cordis [Нью-Йорк]). Кровоток контро-лировали с помощью ангиографии СМА. Через микро-катетер в СМА вводили тромб длиной 3 см. Окклюзию СМА подтверждали результатами ангиографии. После ОСМА в течение 30 минут животным в группе НАДФ путем интраперитонеальной инъекции вводили НАДФ в дозе 1 мг/кг. Все процедуры у обезьян были одобре-ны Комитетом по этике аффиллированной клиники медицинского колледжа Гуйлинь.
Измерение объема очага инфаркта у обезьян с помощью МРТ Всем животным выполнили МРТ на сканере 3Т (Magnetom Verio; Siemens Medical Systems), оснащен-ном 32-канальной системой для получения аксиальных срезов. МР-последовательности и параметры сканиро-вания подробно описаны в таблице I в дополнитель-ных данных on-line. T2-взвешенные и диффузионно-взвешенные изображения получали через 2 часа после ОСМА. Животных затем будили и позволяли восста-новиться. Через 24 часа и через 10 дней после ОСМА всем животным выполнили повторную анестезию и МР-сканирование. Ишемизированные ткани головно-го мозга также давали высокий сигнал на диффузионно-взвешенных изображениях, но зона ишемического по-вреждения на T2-взвешенных изображениях была более заметна; в связи с этим мы измеряли зону ишемичес-кого повреждения по T2-взвешенным изображениям. Все изображения были усилены для подчеркивания гра-ниц очага инфаркта, а измерения выполняли на рабочей станции МР-томографа.
Измерение содержания НАДФ
Мышам внутривенно вводили НАДФ (2,5 мг/кг). Затем мышам (по 6 животных в группе) выполня-ли анестезию с 1% пентобарбиталом натрия и дека-питацию. Извлекали головной мозг и рассекали его на пакете со льдом (-20°С). Содержание НАДФ в голов-ном мозге и крови измеряли в указанные сроки с помощью enzychrom NADPH/NADP assay kit (BioAssay Systems, Hayward, CA) согласно инструкции производителя.
Измерение содержания АТФ
Мышам вводили внутривенно НАДФ (7,5 мг/кг) в начале периода реперфузии. Затем мышам (по 6 жи -вотных в группе) выполняли анестезию с 1% пентобарби-талом натрия и декапитацию через 3 часа после ОСМА/ реперфузии. Извлекали головной мозг и немедленно рас-секали его на пакете со льдом (-20 °С). Из каждого полу-шария полностью извлекали ишемизированную кору (ядро ишемии и зону пенумбры) и быстро замораживали в жидком азоте. Содержание АТФ в коре измеряли через 3 ч после реперфузии с помощью ATP assay kit (Beyotime, Наньтун, Китай), согласно инструкции производителя.
Измерение содержания АФК
Для оценки содержания АФК in vivo, дигидроэтидий (2 мг/кг, Sigma) вводили интраперитонеально за 1 час до окончания эксперимента. Мышам выполняли анес-тезию и декапитацию, срезы головного мозга (10 мкм) получали с помощью криостата (Leica). Флуоресценцию дигидроэтидия в срезах головного мозга оценивали с помощью флуоресцентного микроскопа (Olympus, Токио, Япония).
